← Back to Clinical Trials
Recruiting NCT06375213

NCT06375213 Investigating Neurocognitive Disorders Epidemiology

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06375213
Status Recruiting
Phase
Sponsor King Chulalongkorn Memorial Hospital
Condition Dementia
Study Type OBSERVATIONAL
Enrollment 990 participants
Start Date 2023-08-24
Primary Completion 2035-08-24

Eligibility & Interventions

Sex All sexes
Min Age 35 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Plasma tau phosphorylated at Thr217Neurocognitive examination

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 990 participants in total. It began in 2023-08-24 with a primary completion date of 2035-08-24.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a prospective cohort study with the main purpose of predicting progression neurocognitive disorders in Thai population. The main predictor variables to be evaluated are plasma phosphorylated tau (p-tau) level and cognitive test scores, which will be combined using statistical/computational modeling. Additionally, it seeks to evaluate biomarkers for diagnosing disease pathologies, understand their correlation with clinical outcomes, and explore the socioeconomic impact of neurocognitive disorders. The study invites both participants for biospecimen collection, structured interviews, and cognitive examinations and schedules follow-up visits annually or biennially.

Eligibility Criteria

1. Cognitively Healthy Individuals INCLUSION CRITERIA * Demonstrate normal cognitive function within the expected range on objective cognitive tests. * Proficient in speaking and understanding Thai without the need for a translator to participate. EXCLUSION CRITERIA * Significant neurological or uncontrolled psychiatric illness. * Significant unstable systemic condition or end-stage organ failure that affects study participation. 2. Mild Cognitive Impairment INCLUSION CRITERIA * Display impaired/abnormal performance on objective cognitive tests. * Does not meet criteria for dementia per NIA-AA (or major neurocognitive disorder per DSM-5). * Proficient in speaking and understanding Thai without the need for a translator to participate. EXCLUSION CRITERIA * Significant neurological or uncontrolled psychiatric illness. * Significant unstable systemic condition or end-stage organ failure that affects study participation. 3. Late Onset Dementia INCLUSION CRITERIA * Display impaired/abnormal performance on objective cognitive tests. * Meets criteria for dementia per NIA-AA (or major neurocognitive disorder per DSM-5), including dementia due to Alzheimer's disease or other causes. * Begins to experience symptoms, identified by the physician as a part of dementia continuum, occurring after the age of 65. * Proficient in speaking and understanding Thai without the need for a translator to participate. EXCLUSION CRITERIA * Significant neurological or uncontrolled psychiatric illness. * Significant unstable systemic condition or end-stage organ failure that affects study participation. 4. Early Onset Dementia INCLUSION CRITERIA * Display impaired/abnormal performance on objective cognitive tests. * Meets criteria for dementia per NIA-AA (or major neurocognitive disorder per DSM-5), including dementia due to Alzheimer's disease or other causes. * Begins to experience symptoms, identified by the physician as a part of dementia continuum, occurring before the age of 65. * Proficient in speaking and understanding Thai without the need for a translator to participate. EXCLUSION CRITERIA * Significant neurological or uncontrolled psychiatric illness. * Significant unstable systemic condition or end-stage organ failure that affects study participation.

Contact & Investigator

Central Contact

Poosanu Thanapornsangsuth, M.D.

✉ poosanu.t@chula.ac.th

📞 +66 (0)2 2564000

Principal Investigator

Thiravat Hemachudha, M.D.

PRINCIPAL INVESTIGATOR

Chulalongkorn University

Frequently Asked Questions

Who can join the NCT06375213 clinical trial?

This trial is open to participants of all sexes, aged 35 Years or older, studying Dementia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06375213 currently recruiting?

Yes, NCT06375213 is actively recruiting participants. Contact the research team at poosanu.t@chula.ac.th for enrollment information.

Where is the NCT06375213 trial being conducted?

This trial is being conducted at Pathum Wan, Thailand.

Who is sponsoring the NCT06375213 clinical trial?

NCT06375213 is sponsored by King Chulalongkorn Memorial Hospital. The principal investigator is Thiravat Hemachudha, M.D. at Chulalongkorn University. The trial plans to enroll 990 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology